{"entity":{"id":"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017","kind":"paper","name":"GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma","aka":[],"tldr":"Obinutuzumab with chemotherapy and as maintenance kept follicular lymphoma from progressing for longer than rituximab, at the cost of more serious side effects.","summary":"Open-label phase 3 trial: 1,202 patients with previously untreated follicular lymphoma were randomised to obinutuzumab or rituximab with bendamustine, CHOP or CVP, followed by antibody maintenance.\n\nAt a planned interim analysis after a median follow-up of 34.5 months, estimated three-year progression-free survival was 80.0 percent with obinutuzumab against 73.3 percent with rituximab (hazard ratio 0.66). Response rates were similar (88.5 against 86.9 percent); grade 3 to 5 adverse events (74.6 against 67.8 percent) and serious adverse events (46.1 against 39.9 percent) were more frequent with obinutuzumab, and infusion-related events were the most common adverse event.","asOf":"2026-09-22","links":[{"label":"N Engl J Med 2017","url":"https://doi.org/10.1056/NEJMoa1614598"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/28976863/"}],"tags":[],"related":[],"cancers":["follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["obinutuzumab","rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["gallium"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/NEJMoa1614598","pmid":"28976863","authors":"Marcus R, Davies A, Ando K, et al.","paperType":"rct","findings":["Three-year progression-free survival 80.0 versus 73.3 percent; hazard ratio 0.66 (95% CI 0.51 to 0.85), p 0.001.","Overall response 88.5 versus 86.9 percent.","Grade 3 to 5 adverse events 74.6 versus 67.8 percent; deaths from adverse events 4.0 versus 3.4 percent."],"whatItMeans":"Obinutuzumab-based immunochemotherapy is a first-line option for follicular lymphoma; the choice against rituximab weighs longer progression-free survival against toxicity and cost.","caveats":["No overall survival difference; toxicity was highest with bendamustine partners.","Open-label design with investigator-assessed primary endpoint, supported by independent review."],"changedPractice":true,"participants":1202},"route":"/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"drug":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"trial":[{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}